Propanc Biopharma Files S-1 for Nasdaq IPO Amid Pre-Revenue Status
Propanc Biopharma, Inc. (PRPC) filed an S-1 registration statement with the SEC on October 5, 2026, seeking a Nasdaq listing. The oncology-focused biotech has no approved products, reported $28.7M net loss for FY2025, and held $10.2M in cash. Its pipeline remains pre-clinical.
51CFO view：CFOs of pre-revenue biotechs must demonstrate deep ASC 730 R&D expense classification rigor and robust stock-based compensation modeling under ASC 718. SEC will closely review clinical trial accrual methodologies and assumptions — requiring CFOs to lead cross-functional FP&A teams with clinical operations, not just accountants.
Propanc Biopharma, Inc. (PRPC) filed an S-1 registration statement with the SEC on October 5, 2026, seeking a Nasdaq listing. The oncology-focused biotech has no approved products, reported $28.7M net loss for FY2025, and held $10.2M in cash. Its pipeline remains pre-clinical.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →